The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases

The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases

Abstract It is unclear which factor Xa (FXa) inhibitors are associated with higher bleeding risk in patients with respiratory diseases, and there are no studies on the association between prothrombin time–international normalized ratio (PT–INR) and bleeding risk. We conducted a retrospective cohort...

Full description

Bibliographic Details
Main Authors:	Shohei Hamada, Kei Muramoto, Kimitaka Akaike, Hiroko Okabayashi, Aiko Masunaga, Yusuke Tomita, Hidenori Ichiyasu, Takuro Sakagami
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-02-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-024-54714-5

Similar Items

Successful treatment with dupilumab for mucus plugs in severe asthma
by: Moriyasu Anai, et al.
Published: (2023-01-01)

Primary lung sebaceous carcinoma successfully treated with radiotherapy and pembrolizumab: A case report
by: Yasumiko Jodai, et al.
Published: (2023-01-01)

Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis
by: Moriyasu Anai, et al.
Published: (2022-04-01)

Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
by: Yusuke Tomita, et al.
Published: (2022-12-01)

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study
by: Eva N. Hamulyák, et al.
Published: (2021-01-01)

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland
by: Anne Angelillo-Scherrer, et al.
Published: (2023-07-01)

Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer
by: Kosuke Imamura, et al.
Published: (2022-11-01)

Clinical pathways and outcomes of andexanet alfa administration for reversal of critical bleeding in patients on oral direct factor Xa inhibitors
by: Mark Goldin, et al.

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
by: Tessa Jaspers, et al.
Published: (2021-05-01)

Efficacy and Toxicity of Factor Xa Inhibitors
by: Maryna Bondarenko, et al.
Published: (2013-02-01)

Association of <i>Clostridium butyricum</i> Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations
by: Yusuke Tomita, et al.
Published: (2023-12-01)

Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study
by: Adam J. Singer, et al.
Published: (2023-08-01)

Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation
by: Mahtani, K, et al.
Published: (2017)

Definition of factor Xa inhibitor–related, life‐threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel
by: Gregory J. Fermann, et al.
Published: (2023-10-01)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
by: Shaw Shaw, et al.
Published: (2023-07-01)

Discovery and development of Factor Xa inhibitors (2015–2022)
by: Wei Zheng, et al.
Published: (2023-02-01)

Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor‐associated major bleeding: A real‐world analysis of Medicare beneficiaries
by: James M. Williams, et al.
Published: (2023-06-01)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
by: Katarzyna Papaj, et al.
Published: (2022-01-01)

Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy for Refractory Dyspnea than Patients with Terminal Lung Cancer
by: Hiroko Okabayashi, et al.
Published: (2021-06-01)

Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells
by: Ryoichi Sohma, et al.
Published: (2023-06-01)

The ROX index (Index combining the respiratory rate with oxygenation) is a prognostic factor for acute respiratory distress syndrome.
by: Kenta Nishiyama, et al.
Published: (2023-01-01)

IBM and MVS/XA /
Published: (1987)

A Study on the Effects of Dırect Factor Xa Inhibitors and Direct Thrombin Inhibitors on Human Primary Chondrocyte Cultures
by: Yasin Emre KAYA, et al.
Published: (2019-12-01)

{'en_US': 'THE EFFECT OF A\xa0LACTULOSE-CONTAINING\xa0FOOD ADDITIVE ON THE RHEOLOGICAL PROPERTIES OF\xa0RYE-WHEAT\xa0DOUGH', 'ru_RU': 'ВЛИЯНИЕ ЛАКТУЛОЗОСОДЕРЖАЩЕЙ ПИЩЕВОЙ ДОБАВКИ НА РЕОЛОГИЧЕСКИЕ СВОЙСТВА\xa0РЖАНО-ПШЕНИЧНОГО\xa0ТЕСТА И КАЧЕСТВО ХЛЕБА'}
by: Е.И. Пономарева, et al.
Published: (2022-05-01)

Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa
by: Go Oun Kim, et al.
Published: (2023-04-01)

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator
by: Annika Burger, et al.
Published: (2023-06-01)

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
by: Sebastian Rauch, et al.
Published: (2022-06-01)

Thơ Đường Xa của Nguyễn Duy - Đi xa và nhìn về
by: Nguyễn Thị Hồng Hạnh
Published: (2021-04-01)

Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease‐Activated Receptor Pathway
by: Hiroaki Ichikawa, et al.
Published: (2019-04-01)

Impact of different dose reduction criteria for anti‐Xa direct oral anticoagulants on bleeding complications: A single center observational study
by: Hidehira Fukaya, et al.
Published: (2022-06-01)

IBM and MVS/XA report
by: Computer Technology Research Corp
Published: (1987)

{'en_US': 'SUBSTANTIATION OF THE DESIGN AND TECHNOLOGICAL SCHEME OF AN\xa0ENERGY-SAVING\xa0THERMAL VACUUM UNIT', 'ru_RU': 'ОБОСНОВАНИЕ\xa0КОНСТРУКТИВНО-ТЕХНОЛОГИЧЕСКОЙ\xa0СХЕМЫ ЭНЕРГОСБЕРЕГАЮЩЕГО ТЕРМОВАКУУМНОГО АГРЕГАТА'}
by: А.А. Курочкин, et al.
Published: (2022-03-01)

Assessing the Role of a Malonamide Linker in the Design of Potent Dual Inhibitors of Factor Xa and Cholinesterases
by: Rosa Purgatorio, et al.
Published: (2022-07-01)

{'en_US': 'PRODUCTION OF\xa0ORGANO-MINERAL\xa0FERTILIZERS BY BIOCONVERSION OF POULTRY\n WASTE', 'ru_RU': 'ПРОИЗВОДСТВО\xa0ОРГАНО-МИНЕРАЛЬНОГО\xa0УДОБРЕНИЯ ПУТЕМ БИОКОНВЕРСИИ ОТХОДОВ\n ПТИЦЕВОДСТВА'}
by: А.А. Воробьева
Published: (2021-06-01)

A retrospective multicenter cohort study of the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19
by: Sandra Jonmarker, et al.
Published: (2023-10-01)

Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys
by: Pancras C. Wong, et al.
Published: (2021-05-01)

Management of traumatic cervical epidural hematoma in patients on Xa-inhibitors: a case report and review of the literature
by: Robert Dang, et al.
Published: (2023-11-01)

Identification of new pyrazolyl piperidine molecules as factor Xa inhibitors: Design, synthesis, in silico, and biological evaluation
by: Rahul H. Rayani, et al.
Published: (2022-01-01)

An observational cohort study of interstitial lung abnormalities (ILAs) in a large Japanese health screening population (Kumamoto ILA study in Japan: KILA-J)
by: Kazuya Ichikado, et al.
Published: (2023-06-01)

{'en_US': 'DEVELOPMENT OF AN INSTALLATION FOR\xa0MAGNETO-THERMAL\xa0REINFORCEMENT OF\n POLYMER PARTS OF AGRICULTURAL MACHINES', 'ru_RU': 'РАЗРАБОТКА УСТАНОВКИ ДЛЯ\xa0МАГНИТО-ТЕРМИЧЕСКОГО\xa0АРМИРОВАНИЯ ПОЛИМЕРНЫХ\n ДЕТАЛЕЙ СЕЛЬСКОХОЗЯЙСТВЕННЫХ МАШИН'}
by: Н.В. Воронин, et al.
Published: (2021-09-01)